80 The small sample size (n = 50) may have contributed to this discrepancy
5.0 out of 5 stars Brand is good which delivers quality I like the products from NBL as it delivers quality products which meets the expectation
These numbers come from carefully selected trial populations that excluded many of the profiles described above
GLP-1 drug shows little benefit for people with Parkinsons disease 5 February 2025 The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinsons disease, finds a new study led by UCL researchers

Wegovy Just like with semaglutide, tirzepatide has two brand names: Mounjaro: FDA-approved for Type 2 Diabetes Maximum dose: 15 mg weekly Prescribed primarily for blood sugar control Zepbound: FDA-approved for weight management Same maximum dose: 15 mg weekly Marketed for obesity treatment The drugs are chemically identical, but the legal considerations mirror the Ozempic/Wegovy distinction: Different labels and warnings Different approved uses Potential off-label prescribing Different marketing claims Case Example: Tirzepatide Injury Patient Profile: 52-year-old woman with BMI 34 No diabetes, seeking weight loss Prescribed Zepbound, escalated to 15 mg Timeline: Month 1-3: Excellent weight loss (25 lbs), manageable nausea Month 4: Persistent vomiting began Month 5: Unable to eat solid food, lost 15 more lbs Month 6: Diagnosed with severe gastroparesis via gastric emptying scan Current: 12 months post-discontinuation, still cannot eat normally, requires liquid diet Legal Claim: Inadequate warnings about permanence of gastroparesis Marketing emphasized dramatic weight loss without proper risk disclosure Failure to inform that condition might not resolve after stopping Damages include ongoing medical care, lost wages, diminished quality of life 5

We adjust the schedule based on the patients condition and how they respond to therapy